Improvement of glucose tolerance with immunomodulators in Type 2 diabetic animals

Biotherapy

Volumn 9, Issue 4, 1996, Pages 189-197

  Zhu, Xiao Ping ^a   Satoh, Jo ^b   Muto, Gen ^c   Muto, Yoshiko ^d   Sagara, Mikio ^a   Takahashi, Kazuma ^b   Seino, Hiroaki ^a   Hirai, Satoshi ^c   Masuda, Takayuki ^d   Tanaka, Shun Ichi ^a   Ishida, Hitoshi ^b   Seino, Yutaka ^c   Toyota, Takayoshi ^d  

^a Third Department of Internal Medicine   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Cytokine; Glucose tolerance; Immunomodulator; KK Ay mouse; NIDDM

Indexed keywords

BCG VACCINE; CYTOKINE; GLUCOSE; GLYCOGEN SYNTHASE; IMMUNOMODULATING AGENT; INSULIN; LENTINAN; PICIBANIL; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 2; RECOMBINANT LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVENOUS GLUCOSE TOLERANCE TEST; METABOLISM; MOUSE; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PRIORITY JOURNAL;

EID: 0030477121     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02620732     Document Type: Article

References (34)

1. Eisenbarth GS. Type 1 diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1368.
2. Than S, Ishida H, Inaba M, Fukuba Y, Seino Y, Adachi M, Imura H, Ikehara S. Bone marrow transplantation as a strategy for treatment of non-insulin-dependent diabetes mellitus in KK-Ay mice. J Exp Med 1992; 176: 1233-1238.
3. Kondo K, Nozawa K, Tomida T, Ezaki K. Inbred strains resulting from Japanese mice. Bull Exp Animals 1957; 6: 107-112.
4. Nakamura M, Yamada K. Studies on a diabetic (KK) strain of the mouse. Diabetologia 1967; 3:212-221.
5. Diani AR, Sawada GA, Hannah BA, Jodelis KS, Connell MA, Connell CL, Vidmar TJ, Wyse BM. Analysis of pancreatic islet cells and hormone content in the spontaneously diabetic KK-Ay mouse by morphometry, immunocytochemistry and radioimmunoassay. Wirchows Arch A 1987; 412: 53-61.
6. Toyota T, Satoh J, Oya K, Shintani S, Okano T. Streptococcal preparation (OK-432) inhibits development of type 1 diabetes in NOD mice. Diabetes 1986; 35: 496-499.
7. Satoh J, Shintani S, Oya K, Tanaka S, Nobunaga T, Toyota T, Goto Y. Treatment with Streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and prevents diabetes in BB rats. Diabetes 1988; 37: 1188-1194.
8. Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Ohteki T, Kumagai K, Toyata T. Recombinant human tumor necrosis factor a suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989; 84:1345-1348.
9. Satoh J, Seino H, Shintani S, Tanaka S, Ohteki T, Masuda, T, Nobunaga T, Toyota T. Inhibition of type 1 diabetes in BB rats with human tumor necrosis factor a. J Immunol 1990; 145: 1395-1399.
10. Seino H, Takahashi K, Satoh J, Zhu XP, Sagara M, Masuda, T, Nobunaga T, Funahashi I, Kajikawa T, Toyata T. Prevention of autoimmune diabetes with lymphotoxin in NOD mice. Diabetes 1993; 42: 398
11. Takahashi K, Satoh J, Seino H, Zhu XP, Sagara M, Masuda, T, Toyota T. Prevention of type 1 diabetes with lymphotoxin in BB rats. Clin Immunol Immunopathol 1993; 69: 318-323.
12. Goto Y, Kakizaki M. The spontaneous-diabetes rat: A model of non-insulin dependent diabetes mellitus. Proc J Acad 1981; 57: 381-384.
13. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoka Z. A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 1981; 30: 1045-1050.
14. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid pre-cursors and its possible role in the pathogenesis of hypoplastic anaemias. Brit J Haematol 1987; 67: 11-17.
15. Gaffhey EV, Tsai S-C. Lymphocyte-activating and growthinhibitory activities for several sources of native and recombinant interleukin 1. Cancer Res 1986; 46: 3834-3837.
16. Zhou P, Quackenbush LJ, Zaleski MB. In vitro proliferation of murine spleen cells. Strain variation of proliferative responses induced by recombinant IL-2. Int Arch Allergy App Immunol 1989; 90: 162-168.
17. Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GHW, Chen EY, Goeddel DV. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991; 88: 2830-2834.
18. Desbunguois B, Aurbach CD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971; 33: 732738.
19. Thomas JA, Schleuder KK, Lamer J. A rapid filter paper assay for UDP-glucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. Analytical Biochem 1968; 25: 486-499.
20. Ichimura O, Suzuki S, Sugawara Y, Osawa T. Lymphokines induction by streptococcal preparation OK-432 (picibanil) in mice: Characterization of interleukin 1 (IL-1), interleukin 2 (IL-2) and natural killer cell activating factor (NKAF). In: Hoshino T ed. OK-432. Proceeding of an international symposium held at the 13th International Congress of Chemotherapy, Vienna, September 1983. Amsterdam-Princeton-GenevaTokyo:, Excerpta Medica, 1984: 50-72.
21. Suzuki K, Fukutomi Y, Matsuoka M, Torii K, Hayashi H, Taldi T, Oomoto Y, Onozaki K. Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with Mycobacterium leprae and M. bovis BCG. Int J Lepr Other Mycobact Dis 1993; 61: 609-618.
22. Villar-Palasi C, Larner J. Insulin treatment and increased UDPG-glycogen transglucosylase activity in muscle. Arch Biochem Biophys 1961; 94: 436-442.
23. Rosell-Perez M, Villar-Palasi C, Larner J. Studies on UDPGglycogen transglucosylase. I. Preparation and differentiation of two activities of UDGP-glycogen transglucosylase from rat skeletal muscle. Biochemistry 1962; 1: 763-768.
24. Watanabe Y, Iwa T. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 1984; 53: 248-253.
25. McCallum RE, Berry LJ. Effects of endotoxin on gluconeogenesis, glycogen synthesis, and liver glycogen synthase in mice. Infect Immunol 1973; 7: 642-654.
26. Yamada, K.: Effects of PSK (Krestin) on interleukin production. In: Ishigami J, ed. Recent Advance in Chemotherapy, Anticancer Section 2. Tokyo: Univ. of Tokyo Press, 1985: 876-877.
27. del Rey A, Besedovsky H. Antidiabetic effects of interleukin 1. Proc Natl Acad Sci USA 1989; 86: 5943-5947.
28. Comens PG, Wolf BA, Unanue ER, Lacy PE, McDaniel ML. Interleukin 1 is a potent modulator of insulin secretion from isolated rat islets of Langerhans. Diabetes 1987; 36: 963-970.
29. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor a: A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
30. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output, Endocrinology 1992; 130: 43-52.
31. Williams JG, Jurkovich GJ, Hahnel GB, Maier RV. Macrophage priming by interferon gamma: a selective process with potentially harmful effects. J Leukoc Biol 1992; 52: 579-584.
32. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 707-713.
33. Leahy JL, Bonner-Weir S, Weir GC. Beta cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15:442-455.
34. Hill M, McCallum R. Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. J Clin Invest 1991; 88: 811-816.